PCSK9 Inhibitors: Who Qualifies and What to Expect

PCSK9 inhibitors are the most powerful LDL-lowering medications currently available. They can reduce LDL by 50–60% on top of statin therapy — a magnitude of reduction that was essentially impossible to achieve safely before their introduction.

What PCSK9 is and why blocking it matters

PCSK9 is a protein produced by the liver that degrades LDL receptors. When PCSK9 is blocked, LDL receptors remain active on liver cells, more LDL gets cleared from circulation, and LDL levels fall dramatically.

The two approved PCSK9 inhibitors

Evolocumab (Repatha): Subcutaneous injection every 2 weeks (140mg) or once monthly (420mg). Studied in FOURIER.

Alirocumab (Praluent): Every 2 weeks (75mg or 150mg) or every 4 weeks (300mg). Studied in ODYSSEY OUTCOMES.

Inclisiran: A newer small interfering RNA that reduces PCSK9 production. Given twice yearly by a healthcare provider. Growing in clinical use.

What the trials showed

FOURIER — evolocumab in high-risk patients

FOURIER enrolled 27,564 patients with established ASCVD on statin therapy. Evolocumab reduced LDL from 92 mg/dL to 30 mg/dL (59% reduction). Major cardiovascular events were reduced by 15% over 2.2 years. Heart attack risk reduced by 27%; stroke by 21%. No significant safety concerns at very low LDL. The FOURIER-OLE extension study followed patients up to 8.4 years with maintained benefits and reassuring safety.

ODYSSEY OUTCOMES — alirocumab post-ACS

ODYSSEY OUTCOMES enrolled 18,924 patients who had experienced ACS within the previous 1–12 months. Alirocumab reduced LDL by 55% and major cardiovascular events by 15%. All-cause mortality was reduced by 15% — a finding not seen in FOURIER, possibly reflecting the higher-risk post-ACS population.

Who qualifies — the clinical criteria

Very high-risk ASCVD patients not at LDL goal: LDL ≥70 mg/dL despite maximally tolerated statin + ezetimibe.

Heterozygous familial hypercholesterolemia (HeFH): FH patients who cannot achieve LDL <70 mg/dL on statins + ezetimibe alone.

Statin-intolerant patients at high cardiovascular risk: Ezetimibe + PCSK9 inhibitor may be used without background statin therapy.

Side effects and safety

Injection site reactions: Redness, bruising, or mild pain at the injection site in approximately 2–5% of users. Usually mild and transient.

Neurocognitive effects: FOURIER pre-specified a neurocognitive substudy that found no difference between evolocumab and placebo on any cognitive measure.

Very low LDL — is it safe? Both trials achieved median LDL levels of 25–50 mg/dL with no significant harm identified. Genetic evidence from natural PCSK9 loss-of-function mutations also provides long-term reassurance.

Practical aspects

Storage: Must be refrigerated (2–8°C). Can be kept at room temperature for up to 30 days before use.

Administration: Auto-injector pen, subcutaneous injection (abdomen, upper arm, or thigh). Most patients learn within one session. Injection sites should be rotated.

Monitoring: LDL panel at 4–8 weeks after starting, then every 3–12 months.